A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
Clinical trial NCT07223502 · RECRUITING
Trial details
- NCT number
- NCT07223502
- Sponsor
- Sarfez Pharmaceuticals, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-01
- Primary completion
- 2026-07-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.